1. Volume 95, Issue 2, Pages 412-419 (February 2019)
A distinct bone phenotype in ADPKD patients with end-stage renal disease 
Pieter Evenepoel, Kathleen Claes, Etienne Cavalier, Bjorn Meijers, Peter Stenvinkel, Geert Behets, Magdalena Jankowska, Patrick D’Haese, Bert Bammens 
Kidney International 
Volume 95, Issue 2, Pages (February 2019)
DOI: /j.kint
Copyright © 2019 International Society of Nephrology Terms and Conditions

2. Kidney International 2019 95, 412-419DOI: (10.1016/j.kint.2018.09.018)
Copyright © 2019 International Society of Nephrology Terms and Conditions

3. Figure 1
Levels of bone-specific alkaline phosphatase (BsAP) (a) and tartrate-resistant acid phosphatase 5b (TRAP5b) (b) in patients with end-stage renal disease due to autosomal-dominant polycystic kidney disease (ADPKD) versus control subjects without ADPKD.
Kidney International  , DOI: ( /j.kint )
Copyright © 2019 International Society of Nephrology Terms and Conditions

4. Figure 2
Working model linking autosomal-dominant polycystic kidney disease (ADPKD) to bone phenotype according to stage of disease. In early stage disease, ADPKD associates with low bone turnover, osteopenia, probably as a consequence of disrupted mechanosensation and increased sclerostin expression. In a person with advanced stage disease, ADPKD mitigates hyperparathyroidism-related bone mineral density loss by suppressing bone turnover. CKD, chronic kidney disease; M, mineralization; PTH, parathyroid hormone; T, turnover; V, volume.
Kidney International  , DOI: ( /j.kint )
Copyright © 2019 International Society of Nephrology Terms and Conditions

5. Figure S1
Patient disposition. ADPKD, autosomal dominant polycystic kidney disease; DXA, dual energy x-ray absorptiometry.
Kidney International  , DOI: ( /j.kint )
Copyright © 2019 International Society of Nephrology Terms and Conditions